- Home
- RAND vs VTVT Comparison
RAND vs VTVT Comparison
Compare RAND & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAND
- VTVT
- Stock Information
- Founded
- RAND 1969
- VTVT 2015
- Country
- RAND United States
- VTVT United States
- Employees
- RAND N/A
- VTVT N/A
- Industry
- RAND Finance: Consumer Services
- VTVT Biotechnology: Pharmaceutical Preparations
- Sector
- RAND Finance
- VTVT Health Care
- Exchange
- RAND Nasdaq
- VTVT Nasdaq
- Market Cap
- RAND 57.6M
- VTVT 56.7M
- IPO Year
- RAND N/A
- VTVT 2015
- Fundamental
- Price
- RAND $15.08
- VTVT $16.30
- Analyst Decision
- RAND
- VTVT Strong Buy
- Analyst Count
- RAND 0
- VTVT 2
- Target Price
- RAND N/A
- VTVT $35.50
- AVG Volume (30 Days)
- RAND 6.9K
- VTVT 5.6K
- Earning Date
- RAND 05-05-2025
- VTVT 05-15-2025
- Dividend Yield
- RAND 7.73%
- VTVT N/A
- EPS Growth
- RAND 39.77
- VTVT N/A
- EPS
- RAND 3.12
- VTVT N/A
- Revenue
- RAND $8,499,970.00
- VTVT $17,000.00
- Revenue This Year
- RAND N/A
- VTVT N/A
- Revenue Next Year
- RAND N/A
- VTVT N/A
- P/E Ratio
- RAND $4.85
- VTVT N/A
- Revenue Growth
- RAND 12.52
- VTVT N/A
- 52 Week Low
- RAND $14.01
- VTVT $12.12
- 52 Week High
- RAND $31.89
- VTVT $26.99
- Technical
- Relative Strength Index (RSI)
- RAND 35.97
- VTVT 37.39
- Support Level
- RAND $15.50
- VTVT $15.54
- Resistance Level
- RAND $16.39
- VTVT $16.54
- Average True Range (ATR)
- RAND 1.23
- VTVT 1.00
- MACD
- RAND -0.09
- VTVT -0.54
- Stochastic Oscillator
- RAND 2.12
- VTVT 11.06
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.